We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.24 | 1.35% | 93.08 | 92.10 | 93.20 | 93.18 | 91.92 | 91.97 | 2,031,482 | 16:40:00 |
From May 2019 to May 2024
By Cecilia Butini
Sanofi SA said Wednesday that it has entered into an agreement with BioNTech SE to support the manufacture and supply of the coronavirus vaccine that it is co-developing with Pfizer Inc.
The French pharmaceutical major said it will provide BioNTech with access to its production infrastructure to supply more than 125 million vaccine doses to the European Union. Initial supplies will come from Sanofi's sites in Frankfurt from the summer 2021, it said.
Sanofi added that it is continuing the development of two vaccine candidates against Covid-19, saying that in February 2021 it plans to initiate a new Phase 2 study of the recombinant protein-based vaccine that it is developing with GlaxoSmithKline PLC. The company is also developing a messenger-RNA vaccine in partnership with Translate Bio Inc., it said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
January 27, 2021 02:03 ET (07:03 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
